Literature DB >> 3931140

Prolonged antidopaminergic actions of single doses of butyrophenones in the rat.

A Campbell, R J Baldessarini, M H Teicher, N S Kula.   

Abstract

Rats were treated once with doses of haloperidol or of droperidol below and above the acute ID50 vs the dopamine agonist apomorphine; they were later challenged with an acute dose of apomorphine (0.3 mg/kg, SC) and rated for stereotyped behavioral responses. The two neuroleptics were similar in acute anti-apomorphine potency (ID50 = 0.12 and 0.18 mg/kg for haloperidol and droperidol, respectively). The antidopaminergic effects of droperidol persisted for nearly 1 week and those of haloperidol lasted for 20-40 days, depending on the dose given. The computed half-time of disappearance of their antidopaminergic effects was 7.6 +/- 1.0 days and 0.59 +/- 0.17 days for haloperidol and droperidol, respectively, following a dose of 0.3 mg/kg, and these indices of duration of action did not vary significantly at doses between 0.1 and 1.0 mg/kg. Haloperidol reduced the acute entry of 3H-apomorphine into brain by 21.5% 1 week later. Treatment with apomorphine alone just prior to haloperidol (both at 0.3 mg/kg) prevented the prolonged antidopaminergic effects of the neuroleptic evaluated 1 week later. These results indicate that some neuroleptics may have very prolonged activity or retention in tissue at sites of action, even after moderate, single doses. Caution is recommended in the interpretation of studies which assume "neuroleptic-free" conditions of subjects previously exposed to a neuroleptic agent.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3931140     DOI: 10.1007/bf00431801

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  18 in total

Review 1.  ON THE METABOLISM AND ACTION MECHANISM OF THE PHENOTHIAZINE DRUGS.

Authors:  I S FORREST; F M FORREST
Journal:  Exp Med Surg       Date:  1963

2.  Tolerance to behavioral effects of haloperidol.

Authors:  A Campbell; R J Baldessarini
Journal:  Life Sci       Date:  1981-09-28       Impact factor: 5.037

3.  Tissue levels of haloperidol by radioreceptor assay and behavioral effects of haloperidol in the rat.

Authors:  A Campbell; M Herschel; B M Cohen; R J Baldessarini
Journal:  Life Sci       Date:  1980-08-25       Impact factor: 5.037

4.  Effects of prenatal treatment of rats with haloperidol due to altered drug distribution in neonatal brain.

Authors:  J R Madsen; A Campbell; R J Baldessarini
Journal:  Neuropharmacology       Date:  1981-10       Impact factor: 5.250

5.  Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves.

Authors:  A DeLean; P J Munson; D Rodbard
Journal:  Am J Physiol       Date:  1978-08

6.  Radioreceptor assay of haloperidol tissue levels in the rat.

Authors:  B M Cohen; M Herschel; E Miller; H Mayberg; R J Baldessarini
Journal:  Neuropharmacology       Date:  1980-07       Impact factor: 5.250

7.  A sensitive enzymatic-radioisotopic assay for apomorphine.

Authors:  J W Kebabian
Journal:  J Neurochem       Date:  1978-05       Impact factor: 5.372

8.  Distribution, excretion and metabolism of neuroleptics of the butyrophenone type. I. Excretion and metabolism of haloperidol and nine related butyrophenone-derivatives in the Wistar rat.

Authors:  W Soudijn; I Van Wijngaarden; F Allewijn
Journal:  Eur J Pharmacol       Date:  1967-01       Impact factor: 4.432

9.  Total excretion of 3H-chlorpromazine and 3H-prochlorperazine in chronically dosed animals: balance sheet.

Authors:  I S Forrest; J Fox; D E Green; A P Melikian; M T Serra
Journal:  Adv Biochem Psychopharmacol       Date:  1974

10.  Circadian changes in behavioral effects of haloperidol in rats.

Authors:  A Campbell; R J Baldessarini
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

View more
  10 in total

1.  Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels.

Authors:  J C Baron; J L Martinot; H Cambon; J P Boulenger; M F Poirier; V Caillard; J Blin; J D Huret; C Loc'h; B Maziere
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  Neuroleptic drugs in the human brain: clinical impact of persistence and region-specific distribution.

Authors:  Johannes Kornhuber; Jens Wiltfang; Peter Riederer; Stefan Bleich
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-08       Impact factor: 5.270

3.  Divergent long-term consequences of chronic treatment with haloperidol, risperidone, and bromocriptine on traumatic brain injury-induced cognitive deficits.

Authors:  Thomas I Phelps; Corina O Bondi; Rashid H Ahmed; Yewande T Olugbade; Anthony E Kline
Journal:  J Neurotrauma       Date:  2015-01-08       Impact factor: 5.269

4.  Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride.

Authors:  E S Prosser; R Pruthi; J G Csernansky
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  Sensitization to haloperidol-induced suppression of milk intake: effect of interdose interval.

Authors:  D L Wolgin; J Moore
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

6.  Altered spontaneous behavior and sensitivity to apomorphine in rats following pretreatment with S(+)-aporphines or fluphenazine.

Authors:  A Campbell; R J Baldessarini; J L Neumeyer
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Differences between antipsychotic drugs in persistence of brain levels and behavioral effects.

Authors:  B M Cohen; T Tsuneizumi; R J Baldessarini; A Campbell; S M Babb
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

8.  Combining the Antipsychotic Drug Haloperidol and Environmental Enrichment after Traumatic Brain Injury Is a Double-Edged Sword.

Authors:  Kaitlin A Folweiler; Corina O Bondi; Elizabeth A Ogunsanya; Megan J LaPorte; Jacob B Leary; Hannah L Radabaugh; Christina M Monaco; Anthony E Kline
Journal:  J Neurotrauma       Date:  2016-04-20       Impact factor: 5.269

9.  Dopamine receptor-mediated spinal antinociception in the normal and haloperidol pretreated rat: effects of sulpiride and SCH 23390.

Authors:  S Barasi; M M Ben-Sreti; A L Clatworthy; K N Duggal; J P Gonzalez; J Robertson; K F Rooney; R D Sewell
Journal:  Br J Pharmacol       Date:  1987-01       Impact factor: 8.739

10.  Left globus pallidus abnormality in never-medicated patients with schizophrenia.

Authors:  T S Early; E M Reiman; M E Raichle; E L Spitznagel
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.